Aethlon Medical

Aethlon Medical Current Assets

The Current Assets of Aethlon Medical (AEMD) as of Oct 27, 2026 is 5.57 M USD. In the previous year, Current Assets was 5.95 M USD — a change of -6.39% (lower).

Current Assets

5.57 MUSD

YoY

-6.39%

Last updated:

Current Assets of Aethlon Medical is 2026 5.57 M USD. Current Assets of Aethlon Medical was 2025 5.95 M USD. It decreases by -6.39% lower compared to the previous year.

The Aethlon Medical Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
4.04 M USD
Jan 1, 2020
-219.33 M USD
Jan 1, 2021
-330.39 M USD
Jan 1, 2022
18.16 M USD
Jan 1, 2023
15.09 M USD
Jan 1, 2024
6.23 M USD
Jan 1, 2025
5.95 M USD
Jan 1, 2026
5.57 M USD
The Aethlon Medical Current Assets history
YEARCurrent AssetsYoY
5.57 MUSD-6.39%
5.95 MUSD-4.43%
6.23 MUSD-58.74%
15.09 MUSD-16.90%
18.16 MUSD-105.50%
-330.39 MUSD+50.63%
-219.33 MUSD-5,531.49%
4.04 MUSD-44.11%
7.23 MUSD+352.37%
1.60 MUSD-33.58%
2.40 MUSD+100.21%
1.20 MUSD-19.08%
1.48 MUSD+305.80%
365,739.00USD-47.45%
695,922.00USD+68.44%
413,147.00USD+132.42%
177,761.00USD+311.79%
43,168.00USD-86.90%
329,430.00USD-25.92%
444,676.00USD-48.81%
868,599.00USD+4,517.01%
18,813.00USD+161.26%
7,201.00USD-56.73%
16,642.00USD-89.01%
151,455.00USD+319.74%
36,083.00USD-90.16%
366,697.00USD+11,914.97%
3,052.00USD+381.39%
634.00USD-74.48%
2,484.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aethlon Medical Stock analysis

What does Aethlon Medical do? Aethlon Medical, Inc. generates revenue through its therapeutic and diagnostic segments. The Aethlon segment focuses on the Aethlon Hemopurifier, a device targeting circulating viruses and tumor-secreted exosomes for oncology treatment. The ESI segment, representing diagnostic activities, develops exosome-based product candidates via its subsidiary Exosome Sciences, Inc. (Exosome) for diagnosing neurological disorders and cancer. Customers include healthcare providers seeking innovative treatments for viral infections and cancer progression. The Aethlon Hemopurifier eliminates circulating viruses and exosomes by shedding glycoproteins, addressing both infectious diseases and oncology needs. Exosome Sciences, Inc. (Exosome) develops diagnostic tools using exosomes to monitor neurological conditions and cancer, targeting healthcare institutions and research partners. Revenue streams come from therapeutic device sales and diagnostic product development under the Aethlon and ESI segments. Aethlon Medical, Inc. operates through two business segments: Aethlon for therapeutic products like the Hemopurifier and ESI for diagnostic solutions through Exosome Sciences, Inc. (Exosome). The company's lead product, the Aethlon Hemopurifier, is sold to healthcare providers for treating viral pathogens and cancer metastasis, while Exosome develops exosome-based diagnostics for neurological disorders and cancer monitoring. The firm's revenue is derived from these two segment activities without mentioning external partners or additional financial details. Aethlon Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aethlon Medical stock

Current Assets of Aethlon Medical is 5.57 M USD in 2026.

Current Assets of Aethlon Medical changed from 5.95 M USD to 5.57 M USD, representing a -6.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Aethlon Medical since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Aethlon Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aethlon Medical

All Key Metrics — Aethlon Medical